Dr. Bob Walker will provide updates on this program shortly ... And with this progress, we are already seeing that ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...

Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ... and we undertake no obligation to update or revise any of ...

(Bloomberg) -- Novavax Inc. shares fell as much as 24% after US regulators placed a hold on the company’s experimental influenza and Covid-19 combination vaccines because a study volunteer ...

While it is too early to know how this season’s flu will play out, we do know that COVID-19 is still with us ... vaccines developed by Pfizer and Moderna; and a vaccine developed by Novavax ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug ...

Novavax specified that "[t]he clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial participant outside of the U.S. who ...